Somatostatin receptor-positive breast lesions on 68Ga-DOTATATE PET/CT

被引:2
作者
Simsek, Duygu Has [1 ]
Isik, Emine Goknur [1 ]
Engin, Muge Nur [1 ]
Kuyumcu, Serkan [1 ]
Mudun, Ayse [1 ]
Sanli, Yasemin [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Nucl Med, TR-34093 Istanbul, Turkey
关键词
Somatostatin receptor; Breast lesions; Ga-68-DOTATATE PET; CT; CANCER; SCINTIGRAPHY;
D O I
10.1007/s12149-020-01570-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective This study sets out to evaluate patients with increased uptake in breast lesions on Ga-68-DOTATATE PET/CT (DOTA PET) and determine the clinical significance of somatostatin receptor (SSTR) positive breast lesions. Methods We retrospectively evaluated all patients with increased SSTR uptake in breast lesions on DOTA PET. Patients with physiological (e.g., lactation) or normal variant breast uptake (e.g., mild diffuse glandular uptake) were excluded. The maximum standard uptake value (SUVmax) was calculated using a manually drawn region of interest in the most intense uptake of breast lesions. All lesions were correlated with breast imaging, including mammography and ultrasonography. Histopathological correlation was performed if the lesion was suspicious for malignancy. Lesions were followed up radiologically (1-8 years). Results Out of 1573 retrospectively analyzed DOTA PET scans, the incidence of SSTR + breast lesions was measured as 1.1% (n = 18); however, 4 of 18 patients were excluded due to the lack of final diagnosis of lesions. The median age was 35 (range 14-58 years), and all patients were female. The median SUVmax of SSTR + breast lesions was 5.2 (range 1.5-12.6) for a total of 14 patients. Twelve patients had a single SSTR + breast lesion, while 2 patients had multiple SSTR + lesions on bilateral breasts. In 6 patients, single SSTR + lesions were considered as fibroadenoma; in 2 patients, multiple SSTR + lesions were considered as metastases of NET, based on correlative breast imaging. In 6 patients, histopathological confirmation was needed for the final diagnosis. Histopathologic findings confirmed fibroadenoma in 4 patients by biopsy, in 1 patient with surgical removal of the lesion. The last patient who had a history of IDC was diagnosed with a recurrence of IDC with biopsy. The median SUVmax was 5.1 (range 1.5-9.4) for malignant breast lesions and 5.4 (range 2.2-12.6) for benign breast lesions. Conclusion SSTR + breast lesions on DOTA PET are rarely seen in clinical practice. Uptakes of breast lesions in our cases were variable and not useful for differential diagnosis of lesions. It seems that SSTR + breast lesions should be evaluated with clinical and radiological characteristics, and correlative breast imaging and/or histopathological verification should be performed for suspicious lesions to avoid misdiagnosis.
引用
收藏
页码:270 / 277
页数:8
相关论文
共 50 条
  • [21] Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours
    Kabasakal, Levent
    Demirci, Emre
    Ocak, Meltem
    Decristoforo, Clemens
    Araman, Ahmet
    Ozsoy, Yildiz
    Uslu, Ilhami
    Kanmaz, Bedii
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (08) : 1271 - 1277
  • [22] 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
    Poeppel, Thorsten D.
    Binse, Ina
    Petersenn, Stephan
    Lahner, Harald
    Schott, Matthias
    Antoch, Gerald
    Brandau, Wolfgang
    Bockisch, Andreas
    Boy, Christian
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) : 1864 - 1870
  • [23] 68Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma
    Krokhmal, Aleksandra A.
    Kwatra, Neha
    Drubach, Laura
    Weldon, Christopher B.
    Janeway, Katherine A.
    DuBois, Steven G.
    Kamihara, Junne
    Voss, Stephan D.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (08)
  • [24] A Case Report: Insulinoma in a Military Pilot Detected by 68Ga-Dotatate PET/CT
    Larose, Lisa D.
    Vroman, Penny J.
    Musick, Sierra R.
    Beauvais, Alexis A.
    MILITARY MEDICINE, 2020, 185 (9-10) : E1887 - E1890
  • [25] Uncovering an Optic Nerve Sheath Meningioma Using 68Ga-DOTATATE PET/CT
    Vay, Sabine Ulrike
    Werner, Jan-Michael
    Kabbasch, Christoph
    Schmidt, Matthias
    Drzezga, Alexander
    Fink, Gereon R.
    Galldiks, Norbert
    Warnke, Clemens
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E464 - E465
  • [26] Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT
    Zahed, Hanan
    Beauregard, Jean-Mathieu
    Abikhzer, Gad
    Rush, Christopher
    Probst, Stephan
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (01) : E12 - E15
  • [27] Phenotypic appearances of prostate utilizing PET-MRI and PET-CT with 68Ga-PSMA, radiolabelled choline and 68Ga-DOTATATE
    Haroon, Athar
    Afaq, Asim
    Nuthakki, Soujanya
    Freeman, Alex
    Biassoni, Lorenzo
    Fanti, Stefano
    Beheshti, Mohsen
    Jan, Hikmat
    Vinjamuri, Sobhan
    Emberton, Mark
    Bomanji, Jamshed
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (03) : 196 - 204
  • [28] 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours
    Sharma, Rohini
    Wang, Wai Meng
    Yusuf, Siraj
    Evans, Joanne
    Ramaswami, Ramya
    Wernig, Florian
    Frilling, Andrea
    Mauri, Francesco
    Al-Nahhas, Adil
    Aboagye, Eric O.
    Barwick, Tara D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 141 : 108 - 115
  • [29] Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Wild, Damian
    Bomanji, Jamshed B.
    Benkert, Pascal
    Maecke, Helmut
    Ell, Peter J.
    Reubi, Jean Claude
    Caplin, Martyn E.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (03) : 364 - 372
  • [30] Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management
    Kunikowska, Jolanta
    Lewington, Valerie
    Krolicki, Leszek
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (12) : 905 - 911